| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 43 | 2025 | 872 | 6.730 |
Why?
|
| Genome-Wide Association Study | 63 | 2025 | 369 | 6.240 |
Why?
|
| Alzheimer Disease | 25 | 2025 | 770 | 5.040 |
Why?
|
| Cognitive Dysfunction | 14 | 2026 | 351 | 4.650 |
Why?
|
| Polymorphism, Single Nucleotide | 49 | 2025 | 511 | 3.960 |
Why?
|
| Transcriptome | 15 | 2025 | 409 | 3.860 |
Why?
|
| Genetic Predisposition to Disease | 43 | 2025 | 743 | 3.760 |
Why?
|
| Neuropsychological Tests | 14 | 2026 | 410 | 3.500 |
Why?
|
| Longitudinal Studies | 36 | 2025 | 1286 | 3.410 |
Why?
|
| Cognition | 13 | 2026 | 501 | 3.130 |
Why?
|
| Genetic Variation | 23 | 2025 | 401 | 2.960 |
Why?
|
| Electrocardiography | 14 | 2025 | 558 | 2.620 |
Why?
|
| Male | 143 | 2026 | 31073 | 2.510 |
Why?
|
| Aged | 92 | 2026 | 14946 | 2.420 |
Why?
|
| Female | 145 | 2026 | 34125 | 2.390 |
Why?
|
| Dementia | 6 | 2026 | 272 | 2.340 |
Why?
|
| Middle Aged | 105 | 2026 | 18266 | 2.310 |
Why?
|
| Humans | 197 | 2026 | 65528 | 2.080 |
Why?
|
| Aging | 14 | 2026 | 767 | 2.060 |
Why?
|
| Heart Rate | 6 | 2025 | 331 | 1.960 |
Why?
|
| Machine Learning | 6 | 2026 | 195 | 1.920 |
Why?
|
| Exercise | 6 | 2025 | 964 | 1.800 |
Why?
|
| DNA Methylation | 10 | 2025 | 305 | 1.770 |
Why?
|
| Gene Regulatory Networks | 9 | 2020 | 164 | 1.640 |
Why?
|
| Heart Failure | 9 | 2025 | 943 | 1.570 |
Why?
|
| Biomarkers | 20 | 2025 | 1471 | 1.570 |
Why?
|
| Genetic Loci | 16 | 2020 | 119 | 1.540 |
Why?
|
| Quantitative Trait Loci | 16 | 2024 | 79 | 1.540 |
Why?
|
| Risk Factors | 40 | 2026 | 5442 | 1.500 |
Why?
|
| Aged, 80 and over | 32 | 2026 | 5611 | 1.490 |
Why?
|
| Genomics | 10 | 2024 | 394 | 1.490 |
Why?
|
| Coronary Artery Disease | 5 | 2023 | 326 | 1.420 |
Why?
|
| Smartphone | 5 | 2026 | 72 | 1.380 |
Why?
|
| Cardiovascular Diseases | 12 | 2023 | 866 | 1.290 |
Why?
|
| Heart Atria | 5 | 2023 | 138 | 1.270 |
Why?
|
| Myocardial Infarction | 5 | 2024 | 924 | 1.220 |
Why?
|
| Exome | 10 | 2024 | 78 | 1.160 |
Why?
|
| Gene Expression Profiling | 16 | 2020 | 800 | 1.160 |
Why?
|
| Quantitative Trait, Heritable | 5 | 2023 | 29 | 1.140 |
Why?
|
| Brain | 10 | 2025 | 1606 | 1.110 |
Why?
|
| Multifactorial Inheritance | 7 | 2025 | 28 | 1.100 |
Why?
|
| Cohort Studies | 27 | 2025 | 2635 | 1.060 |
Why?
|
| Genotype | 20 | 2025 | 679 | 1.040 |
Why?
|
| Gene Expression | 9 | 2020 | 864 | 1.030 |
Why?
|
| Whole Genome Sequencing | 6 | 2025 | 86 | 1.020 |
Why?
|
| Inflammation | 9 | 2024 | 1186 | 1.010 |
Why?
|
| tau Proteins | 3 | 2025 | 209 | 1.000 |
Why?
|
| Genetic Association Studies | 7 | 2020 | 121 | 0.980 |
Why?
|
| Gene Expression Regulation | 11 | 2023 | 1635 | 0.940 |
Why?
|
| Fingers | 1 | 2026 | 48 | 0.940 |
Why?
|
| Echocardiography | 7 | 2023 | 512 | 0.940 |
Why?
|
| Blood Proteins | 3 | 2020 | 84 | 0.890 |
Why?
|
| Psychomotor Performance | 1 | 2026 | 139 | 0.880 |
Why?
|
| Adult | 50 | 2025 | 17418 | 0.880 |
Why?
|
| Polysomnography | 1 | 2025 | 59 | 0.880 |
Why?
|
| Amyloid | 1 | 2025 | 71 | 0.860 |
Why?
|
| Wearable Electronic Devices | 2 | 2024 | 76 | 0.860 |
Why?
|
| Phenotype | 17 | 2025 | 1242 | 0.860 |
Why?
|
| Natural Language Processing | 1 | 2024 | 52 | 0.840 |
Why?
|
| Outpatients | 1 | 2025 | 142 | 0.830 |
Why?
|
| Positron-Emission Tomography | 1 | 2025 | 227 | 0.820 |
Why?
|
| Computational Biology | 11 | 2024 | 364 | 0.820 |
Why?
|
| Heart | 4 | 2022 | 295 | 0.810 |
Why?
|
| Vascular Calcification | 1 | 2023 | 26 | 0.800 |
Why?
|
| Metabolomics | 2 | 2021 | 60 | 0.800 |
Why?
|
| Risk Assessment | 12 | 2026 | 2101 | 0.790 |
Why?
|
| Proteomics | 3 | 2020 | 306 | 0.790 |
Why?
|
| MicroRNAs | 8 | 2024 | 710 | 0.760 |
Why?
|
| Sequence Analysis, Protein | 6 | 2008 | 34 | 0.750 |
Why?
|
| Sleep | 2 | 2025 | 239 | 0.750 |
Why?
|
| Patient Compliance | 1 | 2024 | 365 | 0.730 |
Why?
|
| Prospective Studies | 16 | 2025 | 3355 | 0.730 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2024 | 440 | 0.720 |
Why?
|
| Mass Screening | 2 | 2025 | 706 | 0.710 |
Why?
|
| Metabolome | 1 | 2021 | 36 | 0.690 |
Why?
|
| Cognition Disorders | 1 | 2022 | 223 | 0.680 |
Why?
|
| Carrier Proteins | 4 | 2020 | 721 | 0.680 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2025 | 62 | 0.670 |
Why?
|
| White Matter | 2 | 2023 | 125 | 0.660 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2021 | 101 | 0.660 |
Why?
|
| LIM Domain Proteins | 1 | 2020 | 32 | 0.650 |
Why?
|
| Proteins | 10 | 2017 | 764 | 0.640 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 104 | 0.640 |
Why?
|
| Haplotypes | 8 | 2024 | 134 | 0.640 |
Why?
|
| Proteome | 1 | 2021 | 160 | 0.640 |
Why?
|
| Homeodomain Proteins | 5 | 2020 | 277 | 0.640 |
Why?
|
| Artificial Intelligence | 8 | 2023 | 210 | 0.630 |
Why?
|
| Databases, Protein | 10 | 2017 | 48 | 0.620 |
Why?
|
| Mobile Applications | 4 | 2024 | 140 | 0.620 |
Why?
|
| Body Mass Index | 9 | 2025 | 888 | 0.620 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 126 | 0.600 |
Why?
|
| Epigenesis, Genetic | 6 | 2023 | 407 | 0.600 |
Why?
|
| Blood Glucose | 4 | 2025 | 491 | 0.600 |
Why?
|
| Incidence | 12 | 2022 | 1410 | 0.600 |
Why?
|
| Obesity | 8 | 2025 | 1268 | 0.580 |
Why?
|
| Muscle Proteins | 4 | 2020 | 117 | 0.570 |
Why?
|
| Hypertension | 6 | 2025 | 613 | 0.570 |
Why?
|
| Forecasting | 2 | 2019 | 232 | 0.570 |
Why?
|
| Genome, Human | 5 | 2025 | 242 | 0.560 |
Why?
|
| Heart Diseases | 3 | 2017 | 226 | 0.550 |
Why?
|
| Microfilament Proteins | 3 | 2020 | 114 | 0.540 |
Why?
|
| Proportional Hazards Models | 6 | 2025 | 742 | 0.510 |
Why?
|
| Alcoholism | 1 | 2020 | 328 | 0.510 |
Why?
|
| Vaccines | 2 | 2008 | 102 | 0.510 |
Why?
|
| Interleukin-6 | 4 | 2024 | 325 | 0.490 |
Why?
|
| Models, Genetic | 5 | 2021 | 269 | 0.490 |
Why?
|
| Predictive Value of Tests | 7 | 2025 | 1114 | 0.480 |
Why?
|
| Gene Frequency | 8 | 2025 | 124 | 0.480 |
Why?
|
| Choline | 2 | 2025 | 23 | 0.470 |
Why?
|
| Case-Control Studies | 10 | 2026 | 1157 | 0.470 |
Why?
|
| United Kingdom | 2 | 2025 | 85 | 0.450 |
Why?
|
| Prognosis | 7 | 2025 | 1792 | 0.440 |
Why?
|
| Transcription Factors | 5 | 2020 | 1560 | 0.440 |
Why?
|
| Blood Pressure | 7 | 2025 | 526 | 0.440 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2014 | 15 | 0.440 |
Why?
|
| Long QT Syndrome | 3 | 2021 | 31 | 0.440 |
Why?
|
| DNA | 2 | 2019 | 855 | 0.440 |
Why?
|
| Algorithms | 12 | 2020 | 1048 | 0.430 |
Why?
|
| Massachusetts | 10 | 2025 | 2149 | 0.410 |
Why?
|
| C-Reactive Protein | 5 | 2018 | 167 | 0.390 |
Why?
|
| Computers, Handheld | 2 | 2025 | 37 | 0.390 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 2511 | 0.390 |
Why?
|
| Aorta | 2 | 2024 | 114 | 0.390 |
Why?
|
| Peptides | 5 | 2011 | 603 | 0.380 |
Why?
|
| Apolipoprotein E4 | 2 | 2025 | 46 | 0.380 |
Why?
|
| Heart Conduction System | 3 | 2018 | 52 | 0.380 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2018 | 302 | 0.360 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2025 | 366 | 0.360 |
Why?
|
| Precision Medicine | 2 | 2024 | 127 | 0.360 |
Why?
|
| Action Potentials | 2 | 2025 | 112 | 0.360 |
Why?
|
| Models, Cardiovascular | 2 | 2022 | 79 | 0.350 |
Why?
|
| Lipids | 2 | 2019 | 322 | 0.320 |
Why?
|
| Mendelian Randomization Analysis | 5 | 2022 | 12 | 0.320 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2022 | 163 | 0.310 |
Why?
|
| Chromosome Mapping | 4 | 2022 | 297 | 0.310 |
Why?
|
| Body Height | 2 | 2022 | 66 | 0.310 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2008 | 146 | 0.310 |
Why?
|
| CpG Islands | 5 | 2023 | 220 | 0.310 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2022 | 39 | 0.310 |
Why?
|
| Ventricular Function, Left | 3 | 2025 | 275 | 0.300 |
Why?
|
| Reproducibility of Results | 6 | 2025 | 1701 | 0.300 |
Why?
|
| Age Factors | 5 | 2020 | 1593 | 0.300 |
Why?
|
| Oxyhemoglobins | 2 | 2020 | 9 | 0.290 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2017 | 186 | 0.290 |
Why?
|
| Signal Transduction | 5 | 2024 | 3157 | 0.290 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2020 | 29 | 0.280 |
Why?
|
| Presenilin-1 | 2 | 2025 | 68 | 0.270 |
Why?
|
| Linear Models | 6 | 2019 | 409 | 0.270 |
Why?
|
| Mutation | 5 | 2018 | 2679 | 0.270 |
Why?
|
| Software | 5 | 2019 | 395 | 0.270 |
Why?
|
| Immunity | 2 | 2019 | 109 | 0.270 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 2699 | 0.270 |
Why?
|
| Heart Ventricles | 2 | 2021 | 267 | 0.270 |
Why?
|
| Life Style | 2 | 2020 | 320 | 0.260 |
Why?
|
| Atherosclerosis | 2 | 2022 | 158 | 0.260 |
Why?
|
| Antihypertensive Agents | 3 | 2025 | 179 | 0.260 |
Why?
|
| Sex Factors | 4 | 2025 | 996 | 0.250 |
Why?
|
| Linkage Disequilibrium | 5 | 2022 | 48 | 0.250 |
Why?
|
| Factor Xa Inhibitors | 1 | 2007 | 37 | 0.250 |
Why?
|
| Connexin 43 | 2 | 2018 | 14 | 0.250 |
Why?
|
| Reference Values | 3 | 2025 | 331 | 0.250 |
Why?
|
| Cigarette Smoking | 2 | 2017 | 58 | 0.250 |
Why?
|
| Amino Acid Sequence | 9 | 2017 | 1619 | 0.250 |
Why?
|
| Sequence Analysis, DNA | 5 | 2014 | 424 | 0.250 |
Why?
|
| Apolipoproteins E | 2 | 2024 | 114 | 0.240 |
Why?
|
| Coronary Disease | 2 | 2018 | 248 | 0.240 |
Why?
|
| Biological Variation, Population | 2 | 2023 | 9 | 0.240 |
Why?
|
| Alleles | 8 | 2018 | 457 | 0.240 |
Why?
|
| Stroop Test | 1 | 2026 | 8 | 0.240 |
Why?
|
| Stroke | 3 | 2023 | 1213 | 0.240 |
Why?
|
| Internet | 3 | 2008 | 466 | 0.240 |
Why?
|
| Sequence Alignment | 4 | 2007 | 306 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 2247 | 0.240 |
Why?
|
| Polymorphism, Genetic | 4 | 2019 | 197 | 0.240 |
Why?
|
| Myocardium | 2 | 2018 | 298 | 0.230 |
Why?
|
| Prevalence | 5 | 2025 | 1441 | 0.230 |
Why?
|
| Epistasis, Genetic | 2 | 2016 | 44 | 0.230 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2025 | 43 | 0.230 |
Why?
|
| Oxidative Stress | 2 | 2018 | 323 | 0.230 |
Why?
|
| Presenilin-2 | 1 | 2025 | 20 | 0.230 |
Why?
|
| Aorta, Thoracic | 2 | 2024 | 79 | 0.230 |
Why?
|
| Dietary Carbohydrates | 1 | 2025 | 62 | 0.230 |
Why?
|
| Accelerometry | 1 | 2025 | 64 | 0.220 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 134 | 0.220 |
Why?
|
| Oximetry | 1 | 2025 | 49 | 0.220 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 376 | 0.220 |
Why?
|
| Peroxidase | 2 | 2016 | 70 | 0.220 |
Why?
|
| Aortic Aneurysm | 2 | 2022 | 82 | 0.220 |
Why?
|
| Neuroimaging | 2 | 2024 | 159 | 0.220 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2024 | 17 | 0.220 |
Why?
|
| Animals | 15 | 2025 | 21529 | 0.220 |
Why?
|
| Bradycardia | 1 | 2025 | 33 | 0.220 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2025 | 91 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 726 | 0.220 |
Why?
|
| Prediabetic State | 1 | 2025 | 53 | 0.210 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2024 | 10 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 62 | 0.210 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 923 | 0.210 |
Why?
|
| Stroke Volume | 3 | 2025 | 338 | 0.210 |
Why?
|
| HLA Antigens | 3 | 2017 | 63 | 0.210 |
Why?
|
| Time Factors | 6 | 2025 | 3789 | 0.210 |
Why?
|
| Psychometrics | 1 | 2026 | 392 | 0.210 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 431 | 0.210 |
Why?
|
| Databases, Factual | 3 | 2021 | 877 | 0.200 |
Why?
|
| Heterozygote | 2 | 2021 | 175 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 3 | 2024 | 320 | 0.200 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2017 | 369 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2024 | 1020 | 0.200 |
Why?
|
| Sex Characteristics | 2 | 2023 | 211 | 0.200 |
Why?
|
| Viral Load | 1 | 2024 | 231 | 0.200 |
Why?
|
| Diet | 2 | 2025 | 539 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2025 | 239 | 0.200 |
Why?
|
| Decision Support Techniques | 1 | 2025 | 193 | 0.200 |
Why?
|
| Educational Status | 2 | 2023 | 279 | 0.200 |
Why?
|
| Systems Biology | 2 | 2021 | 36 | 0.190 |
Why?
|
| Molecular Sequence Data | 7 | 2008 | 2017 | 0.190 |
Why?
|
| Insulin Resistance | 2 | 2023 | 413 | 0.190 |
Why?
|
| Eicosanoids | 1 | 2022 | 25 | 0.190 |
Why?
|
| Electronic Health Records | 1 | 2026 | 384 | 0.190 |
Why?
|
| ROC Curve | 2 | 2017 | 293 | 0.190 |
Why?
|
| Mental Disorders | 2 | 2020 | 824 | 0.190 |
Why?
|
| Connectin | 2 | 2020 | 14 | 0.190 |
Why?
|
| Ambulatory Care | 1 | 2025 | 320 | 0.190 |
Why?
|
| Drug Design | 3 | 2007 | 139 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6882 | 0.180 |
Why?
|
| Interviews as Topic | 1 | 2024 | 534 | 0.180 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 2 | 2020 | 3 | 0.180 |
Why?
|
| Myocytes, Cardiac | 2 | 2025 | 122 | 0.180 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2022 | 109 | 0.180 |
Why?
|
| ADAMTS Proteins | 2 | 2018 | 4 | 0.180 |
Why?
|
| Quality Control | 2 | 2018 | 78 | 0.170 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2021 | 15 | 0.170 |
Why?
|
| Ventricular Function | 1 | 2021 | 22 | 0.170 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 106 | 0.170 |
Why?
|
| Ventricular Remodeling | 2 | 2020 | 90 | 0.170 |
Why?
|
| Membrane Transport Proteins | 2 | 2024 | 139 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 34 | 0.170 |
Why?
|
| Protein Interaction Maps | 2 | 2017 | 36 | 0.170 |
Why?
|
| Mortality | 2 | 2020 | 161 | 0.170 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 2 | 2025 | 6 | 0.160 |
Why?
|
| Smoking | 3 | 2020 | 866 | 0.160 |
Why?
|
| Atrial Remodeling | 1 | 2020 | 17 | 0.160 |
Why?
|
| Self Report | 1 | 2023 | 393 | 0.160 |
Why?
|
| Antigens, CD1d | 1 | 2020 | 29 | 0.160 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 2783 | 0.160 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1580 | 0.160 |
Why?
|
| Aptamers, Nucleotide | 1 | 2020 | 28 | 0.160 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 67 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 750 | 0.160 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 33 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 2 | 2017 | 93 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 555 | 0.150 |
Why?
|
| Energy Intake | 2 | 2017 | 173 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 381 | 0.150 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2020 | 80 | 0.150 |
Why?
|
| Fitness Trackers | 1 | 2019 | 20 | 0.150 |
Why?
|
| Nutrition Policy | 1 | 2019 | 40 | 0.150 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 163 | 0.150 |
Why?
|
| Quantitative Structure-Activity Relationship | 3 | 2007 | 7 | 0.150 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2019 | 6 | 0.150 |
Why?
|
| Databases, Genetic | 1 | 2019 | 90 | 0.150 |
Why?
|
| United States | 7 | 2022 | 8130 | 0.150 |
Why?
|
| Aftercare | 1 | 2019 | 76 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 3482 | 0.150 |
Why?
|
| Down-Regulation | 1 | 2020 | 328 | 0.150 |
Why?
|
| Membrane Proteins | 3 | 2022 | 928 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 49 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2019 | 43 | 0.150 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2018 | 1 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2025 | 724 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 24 | 0.150 |
Why?
|
| Amino Acids | 3 | 2016 | 149 | 0.150 |
Why?
|
| Genetic Markers | 4 | 2023 | 131 | 0.140 |
Why?
|
| Atrial Function | 1 | 2018 | 5 | 0.140 |
Why?
|
| Atrioventricular Node | 1 | 2018 | 9 | 0.140 |
Why?
|
| Electrophysiological Phenomena | 1 | 2018 | 22 | 0.140 |
Why?
|
| Thyroid Gland | 1 | 2019 | 82 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 149 | 0.140 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 21 | 0.140 |
Why?
|
| Renin | 2 | 2015 | 10 | 0.140 |
Why?
|
| Protein Kinase C-alpha | 1 | 2018 | 17 | 0.140 |
Why?
|
| Ion Channel Gating | 1 | 2018 | 45 | 0.140 |
Why?
|
| Albuminuria | 1 | 2018 | 31 | 0.140 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 133 | 0.140 |
Why?
|
| Filamins | 1 | 2017 | 8 | 0.140 |
Why?
|
| Environmental Exposure | 2 | 2018 | 222 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 322 | 0.140 |
Why?
|
| Morbidity | 1 | 2018 | 111 | 0.140 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 180 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 91 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 315 | 0.140 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 11 | 0.130 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2018 | 104 | 0.130 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 95 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 694 | 0.130 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2017 | 38 | 0.130 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2017 | 14 | 0.130 |
Why?
|
| Demography | 1 | 2018 | 180 | 0.130 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2017 | 6 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2018 | 124 | 0.130 |
Why?
|
| Hand Strength | 1 | 2017 | 34 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 937 | 0.130 |
Why?
|
| Platelet Aggregation | 1 | 2017 | 25 | 0.130 |
Why?
|
| Protein Binding | 4 | 2011 | 1650 | 0.130 |
Why?
|
| Phospholipase A2 Inhibitors | 1 | 2016 | 1 | 0.130 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Oximes | 1 | 2016 | 11 | 0.130 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Benzaldehydes | 1 | 2016 | 3 | 0.130 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2016 | 3 | 0.130 |
Why?
|
| Europe | 4 | 2022 | 201 | 0.130 |
Why?
|
| GATA6 Transcription Factor | 1 | 2016 | 3 | 0.130 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2016 | 7 | 0.130 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2016 | 10 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2018 | 192 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 179 | 0.120 |
Why?
|
| Potassium Channels | 1 | 2016 | 58 | 0.120 |
Why?
|
| Epitopes | 2 | 2008 | 295 | 0.120 |
Why?
|
| Dinoprost | 1 | 2016 | 19 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 136 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 130 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2017 | 106 | 0.120 |
Why?
|
| Oxygen Consumption | 1 | 2016 | 213 | 0.120 |
Why?
|
| Metabolic Syndrome | 2 | 2014 | 147 | 0.120 |
Why?
|
| Oligopeptides | 2 | 2006 | 135 | 0.120 |
Why?
|
| Air Pollution | 1 | 2016 | 37 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 794 | 0.120 |
Why?
|
| Muscle Strength | 1 | 2015 | 40 | 0.120 |
Why?
|
| Disease Progression | 3 | 2025 | 1216 | 0.120 |
Why?
|
| Flavonols | 1 | 2015 | 1 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 624 | 0.110 |
Why?
|
| Neoplasms | 2 | 2017 | 1415 | 0.110 |
Why?
|
| Anthocyanins | 1 | 2015 | 16 | 0.110 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Kininogens | 1 | 2014 | 1 | 0.110 |
Why?
|
| Prekallikrein | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 18 | 0.110 |
Why?
|
| Base Sequence | 3 | 2020 | 1346 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 23 | 0.110 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 557 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 395 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 11 | 1 | 2014 | 3 | 0.110 |
Why?
|
| Computer Simulation | 3 | 2007 | 485 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 58 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2014 | 10 | 0.110 |
Why?
|
| T-Box Domain Proteins | 1 | 2014 | 39 | 0.110 |
Why?
|
| Genetic Pleiotropy | 1 | 2014 | 4 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2014 | 17 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 671 | 0.100 |
Why?
|
| Microglia | 1 | 2017 | 253 | 0.100 |
Why?
|
| Mice | 6 | 2025 | 11215 | 0.100 |
Why?
|
| Vesicular Transport Proteins | 1 | 2014 | 118 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 151 | 0.100 |
Why?
|
| Zebrafish | 4 | 2018 | 373 | 0.100 |
Why?
|
| Chromatin | 3 | 2025 | 643 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 175 | 0.100 |
Why?
|
| Interleukins | 1 | 2013 | 82 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2014 | 180 | 0.100 |
Why?
|
| Boston | 3 | 2024 | 260 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2013 | 167 | 0.100 |
Why?
|
| Systole | 1 | 2012 | 110 | 0.090 |
Why?
|
| Epitope Mapping | 2 | 2011 | 52 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 229 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2014 | 156 | 0.090 |
Why?
|
| Support Vector Machine | 1 | 2012 | 25 | 0.090 |
Why?
|
| Electronics | 2 | 2023 | 33 | 0.090 |
Why?
|
| Enzymes | 1 | 2012 | 36 | 0.090 |
Why?
|
| Organ Size | 2 | 2024 | 173 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2014 | 358 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1025 | 0.090 |
Why?
|
| Genetic Research | 1 | 2011 | 8 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2025 | 1310 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 2283 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 760 | 0.090 |
Why?
|
| Depression | 1 | 2019 | 916 | 0.090 |
Why?
|
| Young Adult | 5 | 2025 | 4836 | 0.090 |
Why?
|
| Allergy and Immunology | 1 | 2011 | 8 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 2015 | 424 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2017 | 816 | 0.090 |
Why?
|
| Models, Molecular | 4 | 2013 | 1174 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 585 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2023 | 265 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 682 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 1173 | 0.080 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 350 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2008 | 274 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2022 | 141 | 0.080 |
Why?
|
| Cardiology | 1 | 2011 | 170 | 0.080 |
Why?
|
| Random Allocation | 2 | 2022 | 201 | 0.080 |
Why?
|
| Molecular Structure | 2 | 2007 | 395 | 0.070 |
Why?
|
| Markov Chains | 1 | 2008 | 36 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2008 | 79 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2006 | 792 | 0.070 |
Why?
|
| Plasma | 2 | 2021 | 39 | 0.070 |
Why?
|
| Antigens | 1 | 2008 | 149 | 0.070 |
Why?
|
| Data Compression | 1 | 2007 | 9 | 0.070 |
Why?
|
| Computer Communication Networks | 1 | 2007 | 12 | 0.070 |
Why?
|
| Database Management Systems | 1 | 2007 | 20 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 96 | 0.070 |
Why?
|
| Age of Onset | 2 | 2018 | 175 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2007 | 60 | 0.070 |
Why?
|
| Mutation, Missense | 2 | 2018 | 189 | 0.070 |
Why?
|
| Developing Countries | 1 | 2007 | 96 | 0.060 |
Why?
|
| Structural Homology, Protein | 1 | 2006 | 22 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 184 | 0.060 |
Why?
|
| Particulate Matter | 2 | 2018 | 66 | 0.060 |
Why?
|
| Metals | 1 | 2006 | 65 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2007 | 115 | 0.060 |
Why?
|
| Pedigree | 2 | 2016 | 199 | 0.060 |
Why?
|
| Binding Sites | 1 | 2008 | 930 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 222 | 0.060 |
Why?
|
| Child | 3 | 2025 | 4678 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 170 | 0.060 |
Why?
|
| Glycemic Index | 1 | 2025 | 23 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 183 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2006 | 140 | 0.060 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2025 | 2 | 0.060 |
Why?
|
| Sick Sinus Syndrome | 1 | 2025 | 5 | 0.060 |
Why?
|
| Reaction Time | 1 | 2025 | 128 | 0.060 |
Why?
|
| Aldosterone | 2 | 2015 | 18 | 0.060 |
Why?
|
| Dilatation, Pathologic | 1 | 2024 | 31 | 0.060 |
Why?
|
| Adiposity | 1 | 2025 | 85 | 0.050 |
Why?
|
| Voice | 1 | 2024 | 6 | 0.050 |
Why?
|
| Speech Acoustics | 1 | 2024 | 9 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2005 | 93 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2025 | 79 | 0.050 |
Why?
|
| Adolescent | 3 | 2025 | 6383 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2025 | 2077 | 0.050 |
Why?
|
| Japan | 2 | 2014 | 64 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2025 | 199 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2006 | 421 | 0.050 |
Why?
|
| Recurrence | 2 | 2016 | 660 | 0.050 |
Why?
|
| Pacemaker, Artificial | 1 | 2025 | 51 | 0.050 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2024 | 33 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2005 | 156 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 769 | 0.050 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2023 | 7 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2024 | 31 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 18 | 0.050 |
Why?
|
| Nucleic Acids | 1 | 2004 | 60 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2008 | 727 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 213 | 0.050 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 161 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 2211 | 0.050 |
Why?
|
| Diglycerides | 1 | 2023 | 24 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2024 | 135 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2022 | 33 | 0.050 |
Why?
|
| Gray Matter | 1 | 2023 | 38 | 0.050 |
Why?
|
| Exercise Test | 1 | 2024 | 257 | 0.050 |
Why?
|
| Sample Size | 1 | 2022 | 67 | 0.050 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2024 | 96 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2023 | 99 | 0.050 |
Why?
|
| Georgia | 1 | 2022 | 88 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 784 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 801 | 0.050 |
Why?
|
| Ventricular Function, Right | 1 | 2022 | 29 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2022 | 72 | 0.050 |
Why?
|
| Social Networking | 1 | 2022 | 23 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2022 | 47 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 524 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 185 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2024 | 977 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2024 | 582 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 11 | 0.040 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2020 | 9 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 63 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 384 | 0.040 |
Why?
|
| Chromosome Structures | 1 | 2020 | 7 | 0.040 |
Why?
|
| Endophenotypes | 1 | 2020 | 9 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 82 | 0.040 |
Why?
|
| Cardiac Myosins | 1 | 2020 | 24 | 0.040 |
Why?
|
| Norway | 1 | 2020 | 23 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 45 | 0.040 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 32 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 156 | 0.040 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 18 | 0.040 |
Why?
|
| Matrix Metalloproteinase 20 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Ankyrins | 1 | 2019 | 3 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2020 | 120 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 155 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 1611 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 81 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 61 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 251 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2019 | 47 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 763 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 81 | 0.040 |
Why?
|
| Integrins | 1 | 2019 | 109 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2019 | 14 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 154 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 19 | 0.040 |
Why?
|
| Iodide Peroxidase | 1 | 2019 | 23 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2019 | 30 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 35 | 0.040 |
Why?
|
| Soot | 1 | 2018 | 8 | 0.040 |
Why?
|
| Thyroxine | 1 | 2019 | 55 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2019 | 43 | 0.040 |
Why?
|
| Aerosols | 1 | 2018 | 46 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 193 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2018 | 51 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2018 | 23 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2018 | 85 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 311 | 0.030 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2018 | 6 | 0.030 |
Why?
|
| Antiporters | 1 | 2018 | 7 | 0.030 |
Why?
|
| Decision Trees | 1 | 2018 | 48 | 0.030 |
Why?
|
| Homozygote | 1 | 2018 | 125 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 393 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 289 | 0.030 |
Why?
|
| A549 Cells | 1 | 2017 | 39 | 0.030 |
Why?
|
| Data Mining | 1 | 2018 | 39 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 182 | 0.030 |
Why?
|
| Introns | 1 | 2018 | 114 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 432 | 0.030 |
Why?
|
| Population Groups | 1 | 2017 | 13 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 259 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 261 | 0.030 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2017 | 1 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2017 | 7 | 0.030 |
Why?
|
| Health Status | 1 | 2020 | 451 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 3 | 0.030 |
Why?
|
| Somatomedins | 1 | 2017 | 4 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2017 | 43 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 8 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 62 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2017 | 51 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2018 | 200 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 228 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2017 | 40 | 0.030 |
Why?
|
| Diethylamines | 1 | 2016 | 3 | 0.030 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2016 | 2 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 8 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2017 | 35 | 0.030 |
Why?
|
| Epinephrine | 1 | 2017 | 47 | 0.030 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 59 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 194 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2016 | 18 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 20 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 44 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 71 | 0.030 |
Why?
|
| Sulfides | 1 | 2016 | 24 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 33 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2016 | 98 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 310 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2016 | 52 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1125 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 65 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 2016 | 11 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 469 | 0.030 |
Why?
|
| Sulfates | 1 | 2016 | 15 | 0.030 |
Why?
|
| Respiration | 1 | 2016 | 93 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 86 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 198 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 249 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 104 | 0.030 |
Why?
|
| Ozone | 1 | 2016 | 19 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 130 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 172 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2018 | 280 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 117 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1576 | 0.030 |
Why?
|
| Carbon | 1 | 2016 | 54 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 157 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2015 | 33 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 134 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 223 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2015 | 38 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2015 | 64 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 159 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 190 | 0.030 |
Why?
|
| Family | 1 | 2017 | 247 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 413 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2007 | 388 | 0.030 |
Why?
|
| Flavanones | 1 | 2015 | 2 | 0.030 |
Why?
|
| Potassium, Dietary | 1 | 2015 | 2 | 0.030 |
Why?
|
| Pyrus | 1 | 2015 | 2 | 0.030 |
Why?
|
| Knee | 1 | 2015 | 40 | 0.030 |
Why?
|
| Malus | 1 | 2015 | 3 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 764 | 0.030 |
Why?
|
| Mississippi | 1 | 2015 | 16 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 66 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 54 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2016 | 95 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 325 | 0.030 |
Why?
|
| Hydrogen Bonding | 2 | 2006 | 129 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2014 | 12 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 312 | 0.030 |
Why?
|
| User-Computer Interface | 2 | 2006 | 126 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 1671 | 0.030 |
Why?
|
| Fruit | 1 | 2015 | 111 | 0.030 |
Why?
|
| Thermodynamics | 2 | 2006 | 199 | 0.030 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type I | 1 | 2014 | 2 | 0.030 |
Why?
|
| Flavones | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2014 | 39 | 0.030 |
Why?
|
| Drosophila | 1 | 2017 | 481 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 879 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 207 | 0.030 |
Why?
|
| Myelin and Lymphocyte-Associated Proteolipid Proteins | 1 | 2013 | 11 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2013 | 7 | 0.030 |
Why?
|
| Interleukin-33 | 1 | 2013 | 19 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 46 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2018 | 2162 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 882 | 0.020 |
Why?
|
| Cell Line | 1 | 2017 | 2071 | 0.020 |
Why?
|
| Zebrafish Proteins | 1 | 2014 | 168 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2013 | 204 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 240 | 0.020 |
Why?
|
| Diastole | 1 | 2012 | 91 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 346 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2011 | 24 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 475 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 1217 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 629 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 697 | 0.020 |
Why?
|
| Folic Acid Antagonists | 1 | 2007 | 8 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 2007 | 47 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2008 | 68 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2007 | 7 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2007 | 16 | 0.020 |
Why?
|
| Pharmacology | 1 | 2007 | 6 | 0.020 |
Why?
|
| Central Nervous System Agents | 1 | 2007 | 11 | 0.020 |
Why?
|
| Biometry | 1 | 2007 | 12 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 2007 | 97 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 53 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 1451 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1718 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1217 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 109 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2006 | 37 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 27 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 122 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2007 | 279 | 0.020 |
Why?
|
| Plant Physiological Phenomena | 1 | 2005 | 5 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5819 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 184 | 0.010 |
Why?
|
| Computing Methodologies | 1 | 2005 | 2 | 0.010 |
Why?
|
| Static Electricity | 1 | 2006 | 169 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 311 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 421 | 0.010 |
Why?
|
| Vibration | 1 | 2004 | 23 | 0.010 |
Why?
|
| HIV-1 | 1 | 2006 | 728 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 720 | 0.010 |
Why?
|